Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Stage-specific alterations in serum levels of G-CSF in chronic myeloid leukaemia

Leukemia volume 17, pages 1430–1432 (2003)Cite this article

TO THE EDITOR

Chronic myeloid leukaemia (CML) is a myeloproliferative disease of stem cell origin, characterised by the presence of the Philadelphia (Ph) chromosome and a BCR–ABL fusion gene that is believed to be causal to the disease. CML cells display changes in many intracellular signalling pathways normally activated by growth factor receptors, suggesting a variety of mechanisms by which these cells might acquire reduced dependence on normal growth factor stimulation or decreased responsiveness to inhibitory factors.1 This is now known to involve the autocrine production of growth factors, specifically IL-3 and G-CSF, by the CD34+ leukaemic cells in chronic phase (CP) CML patients.2,3 Such a mechanism was initially suggested by studies of the effects of enforced expression of p210BCR–ABL in immortalised growth factor-dependent cell lines.4,5 Autocrine production of IL-3 and GM-CSF was later confirmed in p210BCR–ABL-transduced murine bone marrow cells both before and after their transplantation into irradiated mice.6,7 It was therefore of interest to determine whether autocrine growth factor production by primary CML cells in patients also increases their levels in the periphery, and if so, how these change with disease progression. We now describe the interesting results of an analysis of serum samples from a large series of CML patients that show stage-specific changes in circulating levels of G-CSF but not IL-3.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

References

  1. Sattler M, Salgia R . Activation of hematopoietic growth factor signal transduction pathways by the human oncogene BCR/ABL. Cytokine Growth Factor Rev 1997; 8: 63–79.

    Article  CAS  Google Scholar 

  2. Jiang X, Lopez A, Holyoake T, Eaves A, Eaves C . Autocrine production and action of IL-3 and granulocyte colony-stimulating factor in chronic myeloid leukaemia. Proc Nat Acad Sci USA 1999; 96: 12804–12809.

    Article  CAS  Google Scholar 

  3. Jiang X, Fujisaki T, Nicolini F, Berger M, Holyoake T, Eisterer W et al. Autonomous multi-lineage differentiation in vitro of primitive CD34+ cells from patients with chronic myeloid leukemia. Leukemia 2000; 14: 1112–1121.

    Article  CAS  Google Scholar 

  4. Hariharan IK, Adams JM, Cory S . BCR–ABL oncogene renders myeloid cell line factor independent: Potential autocrine mechanism in chronic myeloid leukemia. Oncogene Res. 1988; 3: 387–399.

    CAS  Google Scholar 

  5. Sirard C, Laneuville P, Dick J . Expression of bcr–abl abrogates factor-dependent growth of human hematopoietic M07E cells by an autocrine mechanism. Blood 1994; 83: 1575–1585.

    CAS  PubMed  Google Scholar 

  6. Li S, Ilaria RL, Million RP, Daley GQ, Van Etten RA . The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity. J Exp Med 1999; 189: 1399–1412.

    Article  CAS  Google Scholar 

  7. Zhang X, Ren R . BCR–ABL efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte–macrophage colony-stimulating factor in mice: a novel model for chronic myelogenous leukemia. Blood 1998; 92: 3829–3840.

    CAS  PubMed  Google Scholar 

  8. Chalandon Y, Jiang X, Hazlewood G, Loutet S, Conneally E, Eaves A et al. Modulation of p210-BCR–ABL activity in transduced primary human hematopoietic cells controls lineage programming. Blood 2002; 99: 3197–3204.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We gratefully acknowledge Charlie Pearson and Michael Alcorn, Department of Haematology, Glasgow Royal Infirmary; Marta Taller and Bindy Bains, Terry Fox Laboratory, Vancouver; Alasdair Fraser, Susan Graham and Mark Drummond, GRI; Tim Brümmendorf, University of Tübingen; and Stephen O'Brien, Newcastle Royal Victoria Infirmary.

Author information

Authors and Affiliations

  1. Division of Cancer Sciences & Molecular Pathology, University of Glasgow, Glasgow, UK

    H G Jørgensen, E K Allan & T L Holyoake

  2. Scottish National Blood Transfusion Service, Glasgow Royal Infirmary, Glasgow, UK

    E K Allan

  3. Terry Fox Laboratory, British Columbia Cancer Agency, Vancouver, Canada

    X Jiang, C J Eaves & A C Eaves

  4. Department of Haematology, Glasgow Royal Infirmary, Glasgow, UK

    E Liakopoulou & L Richmond

Authors
  1. H G Jørgensen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E K Allan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. X Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. E Liakopoulou
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. L Richmond
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. C J Eaves
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. A C Eaves
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. T L Holyoake
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jørgensen, H., Allan, E., Jiang, X. et al. Stage-specific alterations in serum levels of G-CSF in chronic myeloid leukaemia. Leukemia 17, 1430–1432 (2003). https://doi.org/10.1038/sj.leu.2402967

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2402967

This article is cited by

Search

Advanced search

Quick links